Evolus (EOLS)
Sells a cosmetic-only neurotoxin and hyaluronic-acid filler line directly to physicians on a cash-pay basis.
$7.93
vs last close−0.33 (−3.94%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 73.96% | 48.85M shares | |
|---|---|---|---|
| 168 holders · as of Jun 30, 2026 | |||
| Insiders | 13.06% | 8.63M shares | |
| 12 holders · as of Sep 4, 2026 | |||
| Other | 12.98% | 8.57M shares | |
| remainder | |||
66.05M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
168 holders · 48.85M shares · 34 new positions · 89 increased · 41 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 5.60M | 8.48% | −774.8K | Aug 19, 2026 |
| BlackRock, Inc. | 4.84M | 7.33% | +550.4K | Aug 7, 2026 |
| Braidwell LP | 3.16M | 4.78% | +50.0K | Aug 14, 2026 |
| Frazier Life Sciences Management, L.P. | 2.63M | 3.98% | 0 | Aug 14, 2026 |
| Perceptive Advisors LLC | 2.46M | 3.72% | +1.17M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.36M | 3.58% | −107.5K | Aug 13, 2026 |
| Millennium Management LLC | 1.79M | 2.71% | +326.8K | Aug 14, 2026 |
| State Street Corp | 1.70M | 2.57% | +376.5K | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Timothy P. Lynch | 9.90% | 6.43M | 13G | Feb 17, 2026 |
| Nantahala Capital Management, LLC | 8.85% | 5.73M | 13G | Nov 14, 2025 |
| BlackRock, Inc. | 6.90% | 4.36M | 13G | Feb 5, 2025 |
| Soleus Capital Master Fund, L.P. | 5.30% | 3.48M | 13G | Aug 31, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 2, 2026 | David Moatazedidirector, officer: See Remarks | Sale | 105,108 | $9.04 | 499,592 |
| Mar 20, 2026 | David Moatazedidirector, officer: See Remarks | Sale | 13,669 | $4.75 | 604,700 |
| Mar 20, 2026 | Rui Avelarofficer: See Remarks | Sale | 3,119 | $4.75 | 427,423 |
| Mar 17, 2026 | Rui Avelarofficer: See Remarks | Sale | 29,996 | $4.89 | 430,542 |
| Mar 17, 2026 | David Moatazedidirector, officer: See Remarks | Sale | 116,720 | $4.89 | 618,369 |
| Dec 22, 2025 | Rui Avelarofficer: See Remarks | Sale | 2,261 | $7.15 | 356,821 |
| Dec 22, 2025 | David Moatazedidirector, officer: See Remarks | Sale | 10,539 | $7.15 | 354,388 |
House and Senate disclosures
Not reported.